Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $3.9 million.

  • Akebia Therapeutics' Current Deferred Revenue changed N/A to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year change of. This contributed to the annual value of $43.3 million for FY2023, which is 105826.65% up from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' Current Deferred Revenue is $3.9 million.
  • Akebia Therapeutics' 5-year Current Deferred Revenue high stood at $75.8 million for Q1 2022, and its period low was $1.2 million during Q1 2025.
  • Moreover, its 5-year median value for Current Deferred Revenue was $43.3 million (2023), whereas its average is $32.5 million.
  • Per our database at Business Quant, Akebia Therapeutics' Current Deferred Revenue skyrocketed by 105826.65% in 2023 and then tumbled by 9717.9% in 2025.
  • Quarter analysis of 5 years shows Akebia Therapeutics' Current Deferred Revenue stood at $20.9 million in 2021, then plummeted by 82.12% to $3.7 million in 2022, then surged by 1058.27% to $43.3 million in 2023, then changed by 0.0% to $43.3 million in 2024, then tumbled by 91.04% to $3.9 million in 2025.
  • Its last three reported values are $3.9 million in Q3 2025, $5.5 million for Q2 2025, and $1.2 million during Q1 2025.